Day: March 10, 2026

– Revenue up 5% to $90.6 Million with a 29% Increase in Income from Operations –– Adjusted EBITDA up 6% to $18.0 Million – DENVER, March 10, 2026 (GLOBE NEWSWIRE) — Concrete Pumping Holdings, Inc. (Nasdaq: BBCP) (the “Company” or “CPH”), a leading provider of concrete pumping and waste management services in the U.S. and U.K., reported financial results for the first quarter ended January 31, 2026. First Quarter Fiscal Year 2026 Summary vs. First Quarter of Fiscal Year 2025 (where applicable)  ● Revenue up 5% to $90.6 million compared to $86.4 million.  ● Gross profit up 2% to $32.0 million compared to $31.2 million.  ● Income from operations up 29% to $4.5 million compared to $3.5 million.  ● Net loss of $2.4 million compared to a net loss of $2.6 million.  ● Net loss...

Kodiak’s AI driver pulls three trailers with one tractorKodiak introduced advanced capabilities that allow the Kodiak Driver to pull three trailers with one tractor, a first in the autonomous vehicle industry, enabling customers to triple their hauling capacity.The Kodiak Driver is now deployed in 20 fully driverless trucks, a 100% increase over Q3. This represents the world’s largest deployment of customer-owned driverless trucks Kodiak Driver-powered trucks have now driven a total of over 10,700 Cumulative Hours of Paid Driverless OperationsMOUNTAIN VIEW, Calif., March 10, 2026 (GLOBE NEWSWIRE) — Kodiak AI, Inc. (“Kodiak” or the “Company”) (Nasdaq: KDK), a leading provider of physical artificial intelligence (“AI”), with a focus on AI-powered autonomous vehicle technology, today announced results for the fourth quarter...

Closing of Purchase Agreement in Post Quantum Cybersecurity Company Mark First Step in the Scale51 Technology Expansion Strategy Company to Host Conference Call Today at 4:30 PM Eastern Time LAKEWOOD, N.J., March 10, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today reported financial results for the year ended December 31, 2025, and provided a strategic update on the Company’s Scale51 initiative, including the launch of EZRA International Group and the closing of the purchase agreement with Enquantum Ltd., a post quantum cybersecurity company. Scale51 represents the Company’s structured framework for expanding into technology driven sectors through disciplined investments and strategic partnerships, while continuing to operate and develop its established insurance...

LEHI, Utah, March 10, 2026 (GLOBE NEWSWIRE) — Nature’s Sunshine Products, Inc. (Nasdaq: NATR) (“Nature’s Sunshine” and/or the “Company”), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Summary vs. Same Year-Ago QuarterNet sales were up 4.7% to $123.8 million compared to $118.2 million (up 3.8% in constant currency). GAAP net income attributable to common shareholders of $4.1 million, or $0.23 per diluted share, compared to net loss of $0.3 million, or $(0.02) per diluted share. Adjusted EBITDA up 16% to $11.9 million compared to $10.3 million.Full Year 2025 Financial Summary vs. 2024Net sales were up 5.7% to $480.1 million compared to $454.4 million (up 5.3%...

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial design for AlloNK expected in first half of 2026 Strengthened board and executive leadership with deep immunology, commercial and financial expertise Robust balance sheet with cash, cash equivalents and investments of $108.0 million as of December 31, 2025, expected to fund operations into Q2 2027 SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December...

Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026  Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (“T1D”), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent corporate developments. “In 2025, vTv delivered meaningful clinical and corporate progress that positions...

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts; Received written FDA Type C meeting minutes; feedback is informing key Phase 2b combination design elements and the Company’s ongoing evaluation of a potential add-on development path with incretin therapy; Presented new body composition data demonstrating differentiated weight maintenance profile for patients that have discontinued combination therapy; Proof-of-concept preclinical data validates Skye’s antigen-peptide conjugate platform, a single unimolecular therapeutic of nimacimab-GLP1RA that delivers additive weight-loss.SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical...

Generated TPOXX Product Revenues of $88 Million in 2025  Received $13 Million International Procurement Order for Oral TPOXX in January 2026   Corporate Update Conference Call Today at 4:30 PM ETNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2025. “In 2025, we continued to advance SIGA’s key long-term priorities, including securing $27 million in additional U.S. Government funding to support development activities, while generating $88 million in product revenues and $24 million in pre-tax operating income,” stated Diem Nguyen, Chief Executive Officer. “In 2026, we are focused on building on our long-standing track record as a successful partner to the...